67914-84-5

Usage

InChI:InChI=1/C20H17Cl2N3O4/c21-15-6-7-17(18(22)8-15)20(11-25-13-23-12-24-25)28-10-16(29-20)9-27-19(26)14-4-2-1-3-5-14/h1-8,12-13,16H,9-11H2/t16-,20-/m1/s1

Upstream product

• 288-88-0 1,2,4-Triazole 
• 170210-39-6 (2R,4R)-(+)-<2-(bromomethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl>methyl benzoate 
• 170210-46-5 cis-2-bromomethyl-2-(2,4-dichlorophenyl)-4-phenylcarbonyloxymethyl-1,3-dioxolane 
• 532-32-1 sodium benzoate 
• 58905-16-1 1-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone 
• 331949-30-5 2-bromomethyl-2-(2,4-dichlorophenyl)-4-phenylcarbonyloxymethyl-1,3-dioxolane 
• 2234-16-4 1-(2,4-dichlorophenyl)ethan-1-one 
• 172032-21-2 (2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-yl)methanol 
• 68751-57-5 2-(2,4-dichlorophenyl)-2-bromomethyl-4-hydroxymethyl-1,3-dioxolane 
• 61397-56-6 (+/-)-cis-[2-(bromomethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolane-4-yl]methyl benzoate 

Relevant academic research and scientific papers

1, 3-DIOXOLANE DERIVATIVE

The present invention provides a compound represented by chemical formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.

An optical pure itraconazole key intermediate and synthetic method and by the intermediate synthesis of optically pure itraconazole method

The invention disclsoes an optically pure itraconazole key intermediate and synthetic method thereof, and a method for synthesizing the optically pure itraconazole from the intermediate. The method of the invention uses 1-(2,4-dichlorobenzene)-2-(1-methylene-1,2,4-triazole)-1-ketone for preparing the optically pure itraconazole key intermediate, and the optically pure itraconazole key intermediate is used for the preparation of optically pure itraconazole. The method uses easily available raw materials, not only reduces the production cost, but also obtains the product with high purity; through the control of the optical purity of the key intermediate compound VII, the optical purity of the target product itraconazole can be effectively controlled; therefore, the invention has with industrial value.

Synthesis, antifungal activity and structure-activity relationships of 2-(alkyl or aryl)-2-(alkyl or polyazol-1-ylmethyl)-4-(polyazol-1-ylmethyl)- 1,3-dioxolanes

A series of 2-(alkyl or aryl)-2-(alkyl or polyazol-1-ylmethyl)-4-(polyazol-1-ylmethyl)-1,3-dioxolanes Ia-u was synthesized and tested in vitro against pathogenic fungi in man, animals and plants: Candida albicans, Aspergillus flavus and Fusarium solani. Compounds Iq-t with two polyazol groups have an in vitro activity against these fungi with MIC (minimum inhibitory concentration) value of 5 μg mL-1.

Stereoselective Syntheses of (+)- and (-)-Terconazole

The recently described cis-benzoates (2R,4R)- and (2S,4S)-2 were transformed into (+)- and (-)-terconazole, respectively by reaction with 1H-1,2,4-triazole followed by hydrolysis to give alcohols (+)- and (-)-3 which were mesylated and reacted with phenol

(2-Aryl-4-phenylthioalkyl-1,3-dioxolan-2-ylmethyl)azole derivatives

The present invention relates to a series of (2-aryl-4-phenylthioalkyl-1,3-dioxolan-2-ylmethyl)azole derivatives which are useful as antifungal and antineoplastic agents.

Heterocyclic derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles

Heterocyclic derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles, useful as antifungal and antibacterial agents.